Pub Date : 2026-02-05DOI: 10.1016/j.ijantimicag.2026.107731
Na Li, Qimao Yang, Bijie Hu, Tongyu Zhu, Nannan Wu
{"title":"Phage Therapy in China: Arming the One Health Approach.","authors":"Na Li, Qimao Yang, Bijie Hu, Tongyu Zhu, Nannan Wu","doi":"10.1016/j.ijantimicag.2026.107731","DOIUrl":"https://doi.org/10.1016/j.ijantimicag.2026.107731","url":null,"abstract":"","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":" ","pages":"107731"},"PeriodicalIF":4.6,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1016/j.ijantimicag.2026.107734
Su Jin Jo, Se Chang Park, Sang Guen Kim
The increasing prevalence of antibiotic-resistant Salmonella Typhimurium has highlighted the urgent need for alternative therapeutic strategies. This study evaluated the antibacterial efficacy of a genetically engineered bacteriophage displaying the antimicrobial peptide, LL37, against S. Typhimurium. Despite displaying LL-37 in the virion structure, the engineered-phage exhibited thermal and pH stabilities comparable to those of the wild-type phage. Notably, it demonstrated enhanced antibacterial activity, primarily owing to an increased adsorption rate. In a cell lysis assay, the engineered-phage sustained bacterial suppression for 24-72 h, whereas the wild-type phage allowed bacterial regrowth, owing to the emergence of phage-resistant mutants. In epithelial cell interaction assays, the engineered-phage significantly reduced bacterial attachment and internalization compared with its wild-type counterpart. Furthermore, intracellular survival assays revealed that the engineered-phage effectively reduced bacterial persistence in host cells. In an in vivo prophylactic assay, the engineered-phage significantly improved larval survival in a Galleria mellonella infection model in a dose-dependent manner, providing protection equivalent to 100 times that of the wild-type phage. Notably, no significant cytotoxicity was observed at either the cellular or animal levels, supporting the safety and therapeutic potential of the engineered-phage. These findings highlight phage engineering as a promising strategy for enhancing antibacterial efficacy and combating antibiotic-resistant bacterial infections.
{"title":"CRISPR/Cas9-Engineered Salmonella Phage Displaying Antimicrobial Peptide LL37 for Enhanced Antibacterial Activity.","authors":"Su Jin Jo, Se Chang Park, Sang Guen Kim","doi":"10.1016/j.ijantimicag.2026.107734","DOIUrl":"https://doi.org/10.1016/j.ijantimicag.2026.107734","url":null,"abstract":"<p><p>The increasing prevalence of antibiotic-resistant Salmonella Typhimurium has highlighted the urgent need for alternative therapeutic strategies. This study evaluated the antibacterial efficacy of a genetically engineered bacteriophage displaying the antimicrobial peptide, LL37, against S. Typhimurium. Despite displaying LL-37 in the virion structure, the engineered-phage exhibited thermal and pH stabilities comparable to those of the wild-type phage. Notably, it demonstrated enhanced antibacterial activity, primarily owing to an increased adsorption rate. In a cell lysis assay, the engineered-phage sustained bacterial suppression for 24-72 h, whereas the wild-type phage allowed bacterial regrowth, owing to the emergence of phage-resistant mutants. In epithelial cell interaction assays, the engineered-phage significantly reduced bacterial attachment and internalization compared with its wild-type counterpart. Furthermore, intracellular survival assays revealed that the engineered-phage effectively reduced bacterial persistence in host cells. In an in vivo prophylactic assay, the engineered-phage significantly improved larval survival in a Galleria mellonella infection model in a dose-dependent manner, providing protection equivalent to 100 times that of the wild-type phage. Notably, no significant cytotoxicity was observed at either the cellular or animal levels, supporting the safety and therapeutic potential of the engineered-phage. These findings highlight phage engineering as a promising strategy for enhancing antibacterial efficacy and combating antibiotic-resistant bacterial infections.</p>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":" ","pages":"107734"},"PeriodicalIF":4.6,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-05DOI: 10.1016/j.ijantimicag.2026.107736
Kishankumar Mahida, Snehal Rajendra Jagtap
{"title":"Comment on 'Pharmacokinetics of Ampicillin, Sulbactam, and Combined Ampicillin/Sulbactam in Subcutis, Muscle, and Plasma: A Microdialysis Trial in Healthy Volunteers'.","authors":"Kishankumar Mahida, Snehal Rajendra Jagtap","doi":"10.1016/j.ijantimicag.2026.107736","DOIUrl":"https://doi.org/10.1016/j.ijantimicag.2026.107736","url":null,"abstract":"","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":" ","pages":"107736"},"PeriodicalIF":4.6,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-04DOI: 10.1016/j.ijantimicag.2026.107733
Yinjia Lou, Yiqing Han
{"title":"Comment on \"Phage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol\".","authors":"Yinjia Lou, Yiqing Han","doi":"10.1016/j.ijantimicag.2026.107733","DOIUrl":"https://doi.org/10.1016/j.ijantimicag.2026.107733","url":null,"abstract":"","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":" ","pages":"107733"},"PeriodicalIF":4.6,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146131775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-03DOI: 10.1016/j.ijantimicag.2026.107724
Lian Liu, Hong Luo
{"title":"Global, regional, and national burden of multidrug-resistant organisms, 1990-2021.","authors":"Lian Liu, Hong Luo","doi":"10.1016/j.ijantimicag.2026.107724","DOIUrl":"https://doi.org/10.1016/j.ijantimicag.2026.107724","url":null,"abstract":"","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":" ","pages":"107724"},"PeriodicalIF":4.6,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146125059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.ijantimicag.2025.107706
Miguel Ángel Consuegra Pérez , Sara Grillo , Alexander Rombauts , María Alba Rivera Martínez , Anna Falcó-Roget , Adaia Albasanz-Puig , Belén Viñado-Pérez , Nuria Fernández-Hidalgo , Laura Camps-Relats , Alba Bergas , Julia Laporte-Amargos , Joaquín López-Contreras , Laura Escolà-Vergé
Objectives
Enterococcus faecalis bloodstream infections (EF-BSIs) are a common cause of infective endocarditis (IE). Recent guidelines consider E. faecalis bacteraemia a major criterion for IE and recommend systematic echocardiographic screening. The objective of this study was to describe the risk of IE in patients with an EF-BSI and an active oncohaematological malignancy.
Methods
We conducted a retrospective multicentre cohort study across three cancer centres in Barcelona, Spain, including all consecutive adults with EF-BSI and active oncohaematological malignancy who had received oncologic treatment within the previous 3 months from January 2014 to December 2023. Patients were identified via microbiology databases. The primary outcome was a diagnosis of definite IE based on European Society of Cardiology criteria. Secondary outcomes included 30-d mortality, 6-month relapse, and cumulative mortality.
Results
A total of 148 patients were included (median age 64.5 y [IQR 57–72]; 53% male). Eighty (54%) patients had a haematological malignancy, and 68 (46%) a solid tumour. Prosthetic heart valves were present in 4 (3%) patients. Most common BSI sources were primary (39, 26%), urinary tract (36, 24%), abdominal or biliary tract (36, 24%), and central venous catheter-related infections (33, 22%). Echocardiography was performed in 22 patients (15%), with only 2 (1%) diagnosed with definite IE: one had a prosthetic valve, and both had persistent bacteraemia. The 30-d mortality rate was 29% and the 6-month cumulative mortality was 55%. Six patients (7%) experienced relapse, with no new IE diagnoses.
Conclusions
Systematic IE screening may not be warranted in this population and should instead be individualised on the basis of clinical risk factors.
{"title":"Risk of infective endocarditis in oncohaematological patients undergoing active treatment with Enterococcus faecalis bloodstream infection: A retrospective multicentre study","authors":"Miguel Ángel Consuegra Pérez , Sara Grillo , Alexander Rombauts , María Alba Rivera Martínez , Anna Falcó-Roget , Adaia Albasanz-Puig , Belén Viñado-Pérez , Nuria Fernández-Hidalgo , Laura Camps-Relats , Alba Bergas , Julia Laporte-Amargos , Joaquín López-Contreras , Laura Escolà-Vergé","doi":"10.1016/j.ijantimicag.2025.107706","DOIUrl":"10.1016/j.ijantimicag.2025.107706","url":null,"abstract":"<div><h3>Objectives</h3><div><em>Enterococcus faecalis</em> bloodstream infections (EF-BSIs) are a common cause of infective endocarditis (IE). Recent guidelines consider <em>E. faecalis</em> bacteraemia a major criterion for IE and recommend systematic echocardiographic screening. The objective of this study was to describe the risk of IE in patients with an EF-BSI and an active oncohaematological malignancy.</div></div><div><h3>Methods</h3><div>We conducted a retrospective multicentre cohort study across three cancer centres in Barcelona, Spain, including all consecutive adults with EF-BSI and active oncohaematological malignancy who had received oncologic treatment within the previous 3 months from January 2014 to December 2023. Patients were identified via microbiology databases. The primary outcome was a diagnosis of definite IE based on European Society of Cardiology criteria. Secondary outcomes included 30-d mortality, 6-month relapse, and cumulative mortality.</div></div><div><h3>Results</h3><div>A total of 148 patients were included (median age 64.5 y [IQR 57–72]; 53% male). Eighty (54%) patients had a haematological malignancy, and 68 (46%) a solid tumour. Prosthetic heart valves were present in 4 (3%) patients. Most common BSI sources were primary (39, 26%), urinary tract (36, 24%), abdominal or biliary tract (36, 24%), and central venous catheter-related infections (33, 22%). Echocardiography was performed in 22 patients (15%), with only 2 (1%) diagnosed with definite IE: one had a prosthetic valve, and both had persistent bacteraemia. The 30-d mortality rate was 29% and the 6-month cumulative mortality was 55%. Six patients (7%) experienced relapse, with no new IE diagnoses.</div></div><div><h3>Conclusions</h3><div>Systematic IE screening may not be warranted in this population and should instead be individualised on the basis of clinical risk factors.</div></div>","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"67 2","pages":"Article 107706"},"PeriodicalIF":4.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145850087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01DOI: 10.1016/j.ijantimicag.2025.107701
Sunish Shah , Rachel V. Marini , Dayna McManus , Ryan K. Shields , Jeffrey E. Topal , Tyler Tate
{"title":"Clinical outcomes of metronidazole dosing strategies in obese patients with Bacteroides bloodstream infections","authors":"Sunish Shah , Rachel V. Marini , Dayna McManus , Ryan K. Shields , Jeffrey E. Topal , Tyler Tate","doi":"10.1016/j.ijantimicag.2025.107701","DOIUrl":"10.1016/j.ijantimicag.2025.107701","url":null,"abstract":"","PeriodicalId":13818,"journal":{"name":"International Journal of Antimicrobial Agents","volume":"67 2","pages":"Article 107701"},"PeriodicalIF":4.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145846608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号